CAP TODAY Pathology/Laboratory Medicine/Laboratory Management
November 2020—Thermo Fisher Scientific announced the availability of its Oncomine Myeloid Assay GX, the first in a series of clinical research assays available from the company’s new portfolio of hematology-oncology assays for the Ion Torrent Genexus System.
The panel enables simultaneous analysis of DNA mutations and RNA fusion transcripts in myeloid samples in one day. It also provides researchers the ability to profile 40 DNA targets and 29 fusion driver genes, enabling the detection of more than 600 fusion isotypes, the company reports, to identify biomarkers associated with myeloproliferative neoplasm, acute myeloid leukemia, and myelodysplastic syndrome.
Pages: 1 2